bluebird bio (NASDAQ:BLUE) Stock Rating Lowered by JPMorgan Chase & Co.

JPMorgan Chase & Co. cut shares of bluebird bio (NASDAQ:BLUE) from an overweight rating to a neutral rating in a report issued on Thursday, Marketbeat.com reports.

bluebird bio Price Performance

BLUE opened at $0.71 on Thursday. The firm has a market cap of $77.53 million, a PE ratio of -0.96 and a beta of 0.81. The business has a fifty day simple moving average of $1.02 and a 200-day simple moving average of $1.09. bluebird bio has a fifty-two week low of $0.68 and a fifty-two week high of $5.53.

Institutional Trading of bluebird bio

Several hedge funds and other institutional investors have recently modified their holdings of the business. Masters Capital Management LLC purchased a new stake in shares of bluebird bio during the fourth quarter worth $1,380,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of bluebird bio by 38.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 325,111 shares of the biotechnology company’s stock worth $416,000 after acquiring an additional 90,139 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of bluebird bio during the fourth quarter worth $317,000. HBK Investments L P purchased a new stake in shares of bluebird bio during the fourth quarter worth $2,070,000. Finally, Vestal Point Capital LP purchased a new stake in shares of bluebird bio during the fourth quarter worth $2,967,000. Institutional investors and hedge funds own 87.43% of the company’s stock.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.